These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7024320)

  • 21. Effect of local immunotherapy of syngeneic rat fibrosarcoma with hapten and antihapten-tumor serum upon nonlocally treated tumor.
    Arai K; Wallace HW
    Cancer Res; 1979 Sep; 39(9):3638-43. PubMed ID: 314334
    [No Abstract]   [Full Text] [Related]  

  • 22. A sensitive enzyme immunoassay for cyclosporin A using antibodies generated against a novel hapten.
    Chen P; Tai HH
    Res Commun Mol Pathol Pharmacol; 1995 Jun; 88(3):317-26. PubMed ID: 8564387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The production of a bispecific anti-CEA, anti-hapten (4-amino-phthalate) hybrid-hybridoma.
    Lloyd F; Goldrosen M
    J Natl Med Assoc; 1991 Oct; 83(10):901-4. PubMed ID: 1800765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hapten-coupled monoclonal anti-I-A antibodies provide a first signal for the induction of suppression.
    Bromberg JS; Nepom JT; Benacerraf B; Greene MI
    J Immunol; 1982 Feb; 128(2):834-7. PubMed ID: 6459387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effect of carrier and hapten preimmunization on delayed hypersensitivity to the carrier.
    Neveu PJ
    Immunology; 1976 Aug; 31(2):257-62. PubMed ID: 955678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ultrasensitive enzyme immunoassay method].
    Kohono T; Ishikawa E
    Tanpakushitsu Kakusan Koso; 1992 Feb; 37(2):144-50. PubMed ID: 1546169
    [No Abstract]   [Full Text] [Related]  

  • 27. DELAYED HYPERSENSITIVITY IN VITRO. 3. THE SPECIFICITY OF HAPTEN-PROTEIN CONJUGATES IN THE INHIBITION OF CELL MIGRATION.
    DAVID JR; LAWRENCE HS; THOMAS L
    J Immunol; 1964 Aug; 93():279-82. PubMed ID: 14202257
    [No Abstract]   [Full Text] [Related]  

  • 28. [Analysis of the specificity of anti-hapten antibody].
    Kitagawa T
    Tanpakushitsu Kakusan Koso; 1987 Sep; (31 Suppl):211-8. PubMed ID: 2827236
    [No Abstract]   [Full Text] [Related]  

  • 29. Experimental approaches to homogenous antibody populations. Myeloma proteins with antihapten antibody activity.
    Eisen HN; Michaelides MC; Underdown BJ; Schulenburg EP; Simms ES
    Fed Proc; 1970; 29(1):78-84. PubMed ID: 5412396
    [No Abstract]   [Full Text] [Related]  

  • 30. A study of the 'termination' of tolerance to BSA with DNP-BSA in rabbits: relative affinities of the antibodies for the immunizing and the paralysing antigens.
    Paul WE; Siskind GW; Benacerraf B
    Immunology; 1967 Aug; 13(2):147-57. PubMed ID: 4952101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hapten-specific B cell blockade of the immune response to a thymus-independent-1 antigen produced by concomitant administration of a thymus-independent-2 antigen.
    Snippe H; Van Houte AJ; Inman JK; Lizzio EF; Merchant B
    Immunology; 1984 May; 52(1):87-96. PubMed ID: 6201438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An immunocytochemical method for localization of estrogen receptors in rat tissues using a dinitrophenyl (DNP)-labeled rat monoclonal primary antibody.
    Gee JM; Nicholson RI; Jasani B; Newman GR; Amselgruber WM
    J Histochem Cytochem; 1990 Jan; 38(1):69-78. PubMed ID: 1688451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New developments in immunoperoxidase techniques and their application.
    Falini B; Taylor CR
    Arch Pathol Lab Med; 1983 Mar; 107(3):105-17. PubMed ID: 6187311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antihapten antibodies in lower vertebrates].
    Frenzel EM; Ambrosius H
    Acta Biol Med Ger; 1971; 26(1):165-71. PubMed ID: 5577786
    [No Abstract]   [Full Text] [Related]  

  • 35. Interaction of purified precipitating and non-precipitating (coprecipitating) antibodies with hapten and with haptenated protein. Evidence of an asymmetric antibody molecule.
    Ronco JR; Sciutto E; Leoni J; Margni RA; Binaghi RA
    Immunology; 1984 Jul; 52(3):449-56. PubMed ID: 6745995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitation of reversible binding by particle counting: hapten-antibody interaction as a model system.
    Sykulev YK; Sherman DA; Cohen RJ; Eisen HN
    Proc Natl Acad Sci U S A; 1992 May; 89(10):4703-7. PubMed ID: 1584807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells.
    Lu Y; Sega E; Low PS
    Int J Cancer; 2005 Sep; 116(5):710-9. PubMed ID: 15828051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining Yeast Display and Competitive FACS to Select Rare Hapten-Specific Clones from Recombinant Antibody Libraries.
    Sun Y; Ban B; Bradbury A; Ansari GA; Blake DA
    Anal Chem; 2016 Sep; 88(18):9181-9. PubMed ID: 27571429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate.
    Le Doussal JM; Martin M; Gautherot E; Delaage M; Barbet J
    J Nucl Med; 1989 Aug; 30(8):1358-66. PubMed ID: 2787847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies with monoclonal antibodies against brush border antigens in Heymann nephritis.
    Bhan AK; Schneeberger EE; Baird LG; Collins AB; Kamata K; Bradford D; Erikson ME; McCluskey RT
    Lab Invest; 1985 Oct; 53(4):421-32. PubMed ID: 3900581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.